CMPS
COMPASS Pathways plc [CMPS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CMPS Stock Summary
Top 10 Correlated ETFs
CMPS
Top 10 Correlated Stocks
CMPS
In the News
CMPS Financial details
Company Rating
Neutral
Market Cap
568.97M
Income
-118.75M
Revenue
3.68M
Book val./share
3.64
Cash/share
3.56
Dividend
-
Dividend %
-
Employees
186
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-4.16
Forward P/E
-
PEG
-3.91
P/S
-
P/B
1.92
P/C
2.34
P/FCF
-5.27
Quick Ratio
17.79
Current Ratio
18.55
Debt / Equity
0.14
LT Debt / Equity
0.13
-
-
EPS (TTM)
-2.39
EPS next Y
-
EPS next Q
-
EPS this Y
7.87%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20.9%
-
-
-
-
SMA20
-10%
SMA50
-18.18%
SMA100
50%
Inst Own
30.19%
Inst Trans
1.57%
ROA
-39%
ROE
-61%
ROC
-0.46%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.01-12.75
52W High
-30.5%
52W Low
+66.8%
RSI
41
Rel Volume
0.28
Avg Volume
725.15K
Volume
205.25K
Perf Week
-9.15%
Perf Month
-23.35%
Perf Quarter
57.81%
Perf Half Y
33.65%
-
-
-
-
Beta
2.485
-
-
Volatility
0.16%, 0.68%
Prev Close
-0.95%
Price
8.34
Change
-2.57%
CMPS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.9 | -1.68 | -1.79 | -2.16 | -2.33 | |
| Operating cash flow per share | -0.82 | -1.15 | -1.69 | -2.48 | -1.92 | |
| Free cash flow per share | -0.83 | -1.16 | -1.7 | -2.5 | -1.92 | |
| Cash per share | 1.15 | 5.3 | 6.83 | 3.37 | 4.32 | |
| Book value per share | -1.4 | 5.47 | 7.11 | 4.27 | 4.42 | |
| Tangible book value per share | -1.4 | 5.47 | 7.11 | 4.27 | 4.42 | |
| Share holders equity per share | -1.4 | 5.47 | 7.11 | 4.27 | 4.42 | |
| Interest debt per share | 0.97 | 0 | 0.09 | -0.1 | 0.65 | |
| Market cap | 630.01M | 1.71B | 883.95M | 340.76M | 446.5M | |
| Enterprise value | 626.14M | 1.52B | 614.32M | 199.49M | 258.91M | |
| P/E ratio | -32.12 | -28.37 | -12.32 | -3.72 | -3.75 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -35.37 | -41.37 | -13.05 | -3.23 | -4.57 | |
| PFCF ratio | -35.04 | -41.24 | -12.98 | -3.21 | -4.56 | |
| P/B Ratio | -20.73 | 8.71 | 3.11 | 1.88 | 1.98 | |
| PTB ratio | -20.73 | 8.71 | 3.11 | 1.88 | 1.98 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -34.05 | -42.92 | -8.13 | -2.06 | -1.89 | |
| EV to operating cash flow | -35.15 | -36.77 | -9.07 | -1.89 | -2.65 | |
| EV to free cash flow | -34.83 | -36.65 | -9.02 | -1.88 | -2.65 | |
| Earnings yield | -0.03 | -0.04 | -0.08 | -0.27 | -0.27 | |
| Free cash flow yield | -0.03 | -0.02 | -0.08 | -0.31 | -0.22 | |
| Debt to equity | -0.69 | 0 | 0.01 | 0.01 | 0.14 | |
| Debt to assets | 0.65 | 0 | 0.01 | 0.01 | 0.11 | |
| Net debt to EBITDA | 0.21 | 5.37 | 3.57 | 1.46 | 1.37 | |
| Current ratio | 1.35 | 29.36 | 19.55 | 12.29 | 13.33 | |
| Interest coverage | 0 | 0 | 0 | 18.3 | -62.12 | |
| Income quality | 0.91 | 0.69 | 0.94 | 1.15 | 0.82 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -2.62 | -1.17 | -1.91 | -1.81 | -0.27 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.33 | 14.38 | 16.94 | 14.4 | 15.23 | |
| ROIC | 2.28 | -0.26 | -0.29 | -0.6 | -0.48 | |
| Return on tangible assets | -0.61 | -0.3 | -0.24 | -0.46 | -0.43 | |
| Graham Net | -1.54 | 5.15 | 6.49 | 3.1 | 3.76 | |
| Working capital | 8.3M | 195.51M | 280.19M | 176.06M | 241.69M | |
| Tangible asset value | -30.39M | 196.56M | 284.41M | 181.28M | 225.74M | |
| Net current asset value | -30.61M | 195.51M | 278.81M | 175.64M | 211.05M | |
| Invested capital | -0.69 | 0 | 0.01 | 0.01 | 0.14 | |
| Average receivables | 3.68M | 5.5M | 8.5M | 13.42M | 22.28M | |
| Average payables | 1.01M | 2.04M | 2.66M | 3.66M | 5.33M | |
| Average inventory | 989.5K | -2.36M | -8.27M | -12.83M | -7.44M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 7.68K | 8.95K | 5.35K | 5.27K | 8.85K | |
| Days of inventory on hand | 6K | -18.75K | -22.49K | -16.46K | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.05 | 0.04 | 0.07 | 0.07 | 0.04 | |
| Inventory turnover | 0.06 | -0.02 | -0.02 | -0.02 | 242.94K | |
| ROE | 0.65 | -0.31 | -0.25 | -0.5 | -0.53 | |
| Capex per share | -0.01 | 0 | -0.01 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.06 | |
| Net income per share | -0.73 | -0.57 | -0.62 | -0.67 | -0.53 | |
| Operating cash flow per share | -1.06 | -0.65 | -0.54 | -0.34 | -0.45 | |
| Free cash flow per share | -1.07 | -0.65 | -0.54 | -0.34 | -0.45 | |
| Cash per share | 3.36 | 2.74 | 3.25 | 5 | 3.56 | |
| Book value per share | 4.25 | 3.78 | 3.65 | 5.1 | 3.64 | |
| Tangible book value per share | 4.25 | 3.78 | 3.65 | 5.1 | 3.64 | |
| Share holders equity per share | 4.25 | 3.78 | 3.65 | 5.1 | 3.64 | |
| Interest debt per share | 0.2 | -0.14 | 0.72 | 0.68 | 0.52 | |
| Market cap | 342.33M | 424.27M | 377.29M | 367.28M | 542.16M | |
| Enterprise value | 201.06M | 308.69M | 261.89M | 151.78M | 354.58M | |
| P/E ratio | -2.77 | -4.38 | -3.33 | -2.75 | -4.13 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 147.22 | |
| POCF ratio | -7.56 | -15.3 | -15.21 | -21.53 | -19.47 | |
| PFCF ratio | -7.54 | -15.29 | -15.19 | -21.51 | -19.47 | |
| P/B Ratio | 1.89 | 2.62 | 2.27 | 1.45 | 2.4 | |
| PTB ratio | 1.89 | 2.62 | 2.27 | 1.45 | 2.4 | |
| EV to sales | 0 | 0 | 0 | 0 | 96.28 | |
| Enterprise value over EBITDA | -8.31 | -10.24 | -8.34 | -5.05 | -8.79 | |
| EV to operating cash flow | -4.44 | -11.13 | -10.55 | -8.9 | -12.73 | |
| EV to free cash flow | -4.43 | -11.12 | -10.55 | -8.89 | -12.73 | |
| Earnings yield | -0.09 | -0.06 | -0.08 | -0.09 | -0.06 | |
| Free cash flow yield | -0.13 | -0.07 | -0.07 | -0.05 | -0.05 | |
| Debt to equity | 0.01 | 0.01 | 0.2 | 0.13 | 0.14 | |
| Debt to assets | 0.01 | 0.01 | 0.16 | 0.11 | 0.11 | |
| Net debt to EBITDA | 5.84 | 3.83 | 3.67 | 7.17 | 4.65 | |
| Current ratio | 12.29 | 14.91 | 15.15 | 18.55 | 13.33 | |
| Interest coverage | -4.91 | 4.27 | 0 | -31.54 | -34.17 | |
| Income quality | 1.46 | 1.15 | 0.88 | 0.51 | 0.85 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.02 | 0 | -0.03 | -0.04 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 3.06 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 7.43 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.11 | -0.6 | -0.17 | -0.1 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 1.14 | |
| Graham number | 8.33 | 6.94 | 7.15 | 8.79 | 6.59 | |
| ROIC | -0.17 | -0.19 | -0.16 | -0.12 | -0.14 | |
| Return on tangible assets | -0.16 | -0.14 | -0.14 | -0.11 | -0.12 | |
| Graham Net | 3.08 | 2.59 | 2.95 | 4.55 | 3.1 | |
| Working capital | 176.06M | 156.57M | 180.83M | 269.46M | 241.69M | |
| Tangible asset value | 181.28M | 161.64M | 166.4M | 253.26M | 225.74M | |
| Net current asset value | 175.64M | 156.16M | 150.16M | 239.03M | 211.05M | |
| Invested capital | 0.01 | 0.01 | 0.2 | 0.13 | 0.14 | |
| Average receivables | 16.87M | 17.99M | 26.59M | 28.92M | 26.98M | |
| Average payables | 12.32M | 4.32M | 2.93M | 3.12M | 5.07M | |
| Average inventory | 5.55M | -17.45M | -4.81M | 10.03M | 4.83M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 706.97 | |
| Days payables outstanding | 4.43K | 588.78 | 301.88 | 580.89 | 287.98 | |
| Days of inventory on hand | -13.84K | -3.04K | 1.58K | 1.32K | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0.13 | |
| Payables turnover | 0.02 | 0.15 | 0.3 | 0.15 | 0.31 | |
| Inventory turnover | -0.01 | -0.03 | 0.06 | 0.07 | 1.84M | |
| ROE | -0.17 | -0.15 | -0.17 | -0.13 | -0.15 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CMPS Frequently Asked Questions
What is COMPASS Pathways plc stock symbol ?
COMPASS Pathways plc is a GB stock and trading under the symbol CMPS
What is COMPASS Pathways plc stock quote today ?
COMPASS Pathways plc stock price is $8.34 today.
Is COMPASS Pathways plc stock public?
Yes, COMPASS Pathways plc is a publicly traded company.
Company Profile
- Volume Average 725.15K
- Market Capitalization 568.97M
- Employee 186
- CEO Mr. Kabir Nath M.A., M.B.A.
- Headquarters London,GB
- IPO Date 2020-09-18
-
Website
https://compasspathways.com 
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
